Inovio Fights Investor Class Cert. In COVID-19 Vaccine Suit
Biotechnology firm Inovio Pharmaceuticals Inc. and a cohort of company executives doubled down on their arguments to a Pennsylvania federal court Friday and urged against class certification for investors bringing claims...To view the full article, register now.
Already a subscriber? Click here to view full article